Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant to identify drugs with sedative or anticholinergic effects that require patient counseling. The correct answer, hydroxyzine 25 mg three times daily as needed, represents optimal pharmacist decision-making as it is an antihistamine with significant sedation and anticholinergic risks. Hydralazine and losartan are incorrect as they are vasodilator and angiotensin II receptor blocker classes for hypertension, without sedative effects. Sertraline is also incorrect because it is a selective serotonin reuptake inhibitor for anxiety, with minimal anticholinergic activity. A clinical pearl is that first-generation antihistamines like hydroxyzine can cause drowsiness, especially in older adults. For similar mix-ups, pharmacists should counsel on class-specific side effects and monitor for uncontrolled symptoms like hypertension.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for distinguishing drugs with similar names but different risks, like dependence. The correct answer, benzodiazepine, represents optimal pharmacist decision-making by classifying clonazepam correctly for panic disorder counseling. Alpha-2 adrenergic agonist and selective serotonin reuptake inhibitor are incorrect as they describe clonidine and sertraline, respectively. Triptan is also incorrect because it applies to sumatriptan for migraines, not anxiolytics. A clinical pearl is that benzodiazepines like clonazepam carry risks of tolerance and withdrawal. In similar confusions, pharmacists should emphasize class-specific warnings like avoiding alcohol.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for identifying fetal risks in pregnant patients with hypertension. The correct answer, losartan 50 mg daily (angiotensin II receptor blocker), represents optimal pharmacist decision-making as it is contraindicated in pregnancy due to teratogenicity. Labetalol and nifedipine ER are incorrect as beta-blocker and calcium channel blocker classes, safer in pregnancy. Methyldopa is also incorrect because it is a preferred central alpha-2 agonist for gestational hypertension. A clinical pearl is that ARBs can cause oligohydramnios and renal defects in fetuses. In similar decisions, pharmacists should consult ACOG guidelines for class safety in pregnancy.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for guiding formulary substitutions without altering therapy efficacy in gout management. The correct answer, colchicine 0.6 mg tablets twice daily, represents optimal pharmacist decision-making as it maintains the same anti-inflammatory drug for prophylaxis. Allopurinol and indomethacin are incorrect as they are xanthine oxidase inhibitor and NSAID classes, respectively. Prednisone is also incorrect because it is a corticosteroid, not a direct substitute for colchicine. A clinical pearl is that colchicine formulations may differ in bioavailability, requiring dose verification. For similar restrictions, pharmacists should prioritize same-drug switches before class alternatives.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for distinguishing systemic from local effects in corticosteroid use. The correct answer, prednisone 40 mg daily for 5 days, represents optimal pharmacist decision-making as it identifies the systemic glucocorticoid class for asthma exacerbations. Albuterol HFA and montelukast are incorrect as beta-agonist and leukotriene inhibitor classes, respectively. Ipratropium nasal spray is also incorrect because it is an anticholinergic for rhinitis, not systemic. A clinical pearl is that systemic corticosteroids can elevate glucose in short bursts. For similar questions, pharmacists should clarify route and class to address patient concerns.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for differentiating inhalers and ensuring proper COPD control. The correct answer, tiotropium (Spiriva) 2 inhalations once daily, represents optimal pharmacist decision-making as it identifies the long-acting muscarinic antagonist class. Albuterol HFA and budesonide/formoterol are incorrect as short-acting beta-agonist and ICS/LABA classes, respectively. Fluticasone nasal spray is also incorrect because it is an intranasal corticosteroid for allergies. A clinical pearl is that LAMAs like tiotropium are foundational for COPD maintenance. In similar confusions, pharmacists should demonstrate device use and confirm class per GOLD guidelines.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for preventing hyperkalemia and duplication in renin-angiotensin system inhibition. The correct answer, lisinopril 20 mg daily, represents optimal pharmacist decision-making by identifying it as the ACE inhibitor class. Losartan and amlodipine are incorrect as angiotensin II receptor blocker and calcium channel blocker classes, respectively. Metformin is also incorrect because it is a biguanide for diabetes, not antihypertensives. A clinical pearl is that combining ACE inhibitors and ARBs increases hyperkalemia risk in nephropathy. For similar cases, pharmacists should monitor potassium and recommend single-class therapy.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for differentiating urate-lowering from anxiolytic agents. The correct answer, xanthine oxidase inhibitor, represents optimal pharmacist decision-making by classifying allopurinol for gout. Benzodiazepine and uricosuric agent are incorrect as they describe alprazolam and probenecid, respectively. Nonsteroidal anti-inflammatory drug is also incorrect because it applies to ibuprofen, not allopurinol. A clinical pearl is that allopurinol requires HLA-B*5801 testing in high-risk populations for hypersensitivity. For similar confusions, pharmacists should counsel on class-specific monitoring like uric acid levels.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for clarifying drug purposes and avoiding mix-ups with similar names. The correct answer, selective alpha-1 adrenergic blocker, represents optimal pharmacist decision-making by classifying tamsulosin for BPH symptoms. Selective estrogen receptor modulator and 5-alpha-reductase inhibitor are incorrect as they describe tamoxifen and finasteride, respectively. Antimuscarinic is also incorrect because it applies to oxybutynin for bladder issues. A clinical pearl is that alpha-1 blockers like tamsulosin can cause orthostasis, especially with antihypertensives. For similar queries, pharmacists should differentiate classes by indication and mechanism.

Drug names include generic and brand designations, while therapeutic classes categorize medications based on their mechanism of action and clinical indications. Understanding therapeutic classes is clinically relevant for assessing contraindications in patients with respiratory comorbidities. The correct answer, propranolol 40 mg twice daily (nonselective beta-blocker), represents optimal pharmacist decision-making as it is inappropriate in asthma due to bronchospasm risk. Albuterol HFA and fluticasone/salmeterol are incorrect as beta-2 agonist and ICS/LABA classes, beneficial for asthma. Primidone is also incorrect because it is an anticonvulsant, not directly contraindicated. A clinical pearl is that nonselective beta-blockers block beta-2 receptors, exacerbating asthma. In similar cases, pharmacists should recommend cardioselective beta-blockers like metoprolol.